Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04261244 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NeoRad Breast Cancer Study

Study acronym: NeoRad
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Prof. Dr. Christiane Matuschek to Bielefeld University
    • Study sites: 1 to 16
    • Study description expanded, about 31 words
    • Eligibility criteria shortened, about 5 words
    v4
  2. Lead sponsor: Heinrich-Heine University, Duesseldorf to Prof. Dr. Christiane Matuschekv3 Show 6 more changesShow less
    • Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Jun 30, 2030 to Mar 31, 2028
    • Start date changed from estimate of Jul 1, 2020 to Feb 1, 2024
    • Study completion date: Dec 31, 2030 to Mar 31, 2034
    • Study site revised
    • Eligibility criteria expanded, about 4 words
  3. Secondary endpoints: 11 to 12v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The NEORAD trial tests whether preoperative radiotherapy results in an improved DFS and less radiation induced late effect compared to postoperative radiotherapy in higher risk breast cancer after NACT.
Trial Details
NCT Number NCT04261244
Lead Sponsor Bielefeld University
Conditions
(from sponsor)		 Breast Cancer
Related terms Breast Neoplasms
Enrollment 1,826 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov